Transthyretin Regulated by linc00657/miR-205-5p Promoted Cholesterol Metabolism by Inducing SREBP2-HMGCR and Inhibiting LXRα-CYP7A1.


Journal

Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706

Informations de publication

Date de publication:
05 2020
Historique:
received: 15 04 2019
revised: 04 02 2020
accepted: 24 02 2020
pubmed: 4 4 2020
medline: 17 9 2020
entrez: 4 4 2020
Statut: ppublish

Résumé

Transthyretin functions as a serum transport protein for retinol. Transthyretin has been found associated with amyloid diseases and it is an important nutrition indicator. For this study, we aimed to investigate the up and down stream molecular mechanisms of Transthyretin in cholesterol metabolism. We have recruited 237 fatty liver patients to evaluate the serum Transthyretin and its association with cholesterol and other clinical characteristics. And then Transthyretin was up and down regulated by plasmids to investigate its downstream mechanisms in vitro. Linc00657 (NORAD) and miR-205-5p were further confirmed as upstream mechanisms to regulate Transthyretin. High level Transthyretin patients tended to have higher cholesterol, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) level than low level Transthyretin patients. Moreover, Transthyretin expressed higher in LO2 than that in QSG7701. Furthermore, Transthyretin negatively regulated CYP7A1, LXRα and ABCG 5/8 and positively regulated HMGCR and SREBP2. Linc00657 expressed lower in LO2 than that in QSG7701 and miR-205-5p expressed higher in LO2 than that in QSG7701. Furthermore, we found that linc00657 negatively regulated miR-205-5p and Transthyretin in vitro. And, up regulation of miR-205-5p in linc00657-LO2 cell line could reverse the inhibitory effects of linc00657 on Transthyretin. Transthyretin regulated cholesterol metabolism mainly through inhibiting LXRα-CYP7A1 and promoting SREBP2-HMGCR. And linc00657 could negatively regulate Transthyretin by inhibiting miR-205-5p, providing novel therapeutic targets for decreasing serum cholesterol level. Besides, Transthyretin could be a potential novel biomarker for predicting liver function along with AST and ALT.

Sections du résumé

BACKGROUND
Transthyretin functions as a serum transport protein for retinol. Transthyretin has been found associated with amyloid diseases and it is an important nutrition indicator. For this study, we aimed to investigate the up and down stream molecular mechanisms of Transthyretin in cholesterol metabolism.
METHODS
We have recruited 237 fatty liver patients to evaluate the serum Transthyretin and its association with cholesterol and other clinical characteristics. And then Transthyretin was up and down regulated by plasmids to investigate its downstream mechanisms in vitro.
RESULTS
Linc00657 (NORAD) and miR-205-5p were further confirmed as upstream mechanisms to regulate Transthyretin. High level Transthyretin patients tended to have higher cholesterol, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) level than low level Transthyretin patients. Moreover, Transthyretin expressed higher in LO2 than that in QSG7701. Furthermore, Transthyretin negatively regulated CYP7A1, LXRα and ABCG 5/8 and positively regulated HMGCR and SREBP2. Linc00657 expressed lower in LO2 than that in QSG7701 and miR-205-5p expressed higher in LO2 than that in QSG7701. Furthermore, we found that linc00657 negatively regulated miR-205-5p and Transthyretin in vitro. And, up regulation of miR-205-5p in linc00657-LO2 cell line could reverse the inhibitory effects of linc00657 on Transthyretin.
CONCLUSION
Transthyretin regulated cholesterol metabolism mainly through inhibiting LXRα-CYP7A1 and promoting SREBP2-HMGCR. And linc00657 could negatively regulate Transthyretin by inhibiting miR-205-5p, providing novel therapeutic targets for decreasing serum cholesterol level. Besides, Transthyretin could be a potential novel biomarker for predicting liver function along with AST and ALT.

Identifiants

pubmed: 32241558
pii: S0188-4409(19)30394-7
doi: 10.1016/j.arcmed.2020.02.009
pii:
doi:

Substances chimiques

MIRN205 microRNA, human 0
MicroRNAs 0
Prealbumin 0
Cholesterol 97C5T2UQ7J
HMGCR protein, human EC 1.1.1.-
Hydroxymethylglutaryl CoA Reductases EC 1.1.1.-
CYP7A1 protein, human EC 1.14.14.23
Cholesterol 7-alpha-Hydroxylase EC 1.14.14.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-326

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Huang Zuo (H)

Department of Operation, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.

Xiaohong Su (X)

Department of Clinical Laboratory, Liaocheng People's Hospital, Liaocheng, China.

Yixiao Jin (Y)

Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.

Cheng Zhang (C)

Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.

Lelin Wang (L)

Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.

Lin Yang (L)

Department of Vascular Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. Electronic address: yanglinxjtu@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH